Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Autologous Blood Transfusion

Research Leaders

8 sponsors active, led by Anti-Doping Lab Qatar

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Early Phase 1 (1)
Phase 3 (1)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03548766Phase 3Unknown

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

NCT02684747Early Phase 1Completed

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

Showing all 2 trials

Research Network

Common Treatments

  • Autologous Blood Transfusion1
  • Control Normal Saline Placebo1
  • Homologous Blood Transfusion1
  • Autologous Transfusion1

Active Sponsors

  • Anti-Doping Lab Qatar1
  • Hamad Medical Corporation1
  • Sidra Medicine1
  • World Anti-Doping Agency1
  • University of Utah1

Top Investigators

Related Conditions

  • Blood Transfusion Autologous2
  • Blood Transfusion Homologous1
  • Blood Disease1

Activity Timeline